Effect of estrogen on intestinal strontium absorption in postmenopausal women.
OBJECTIVE
there is considerable uncertainty about the underlying cause of decreased intestinal calcium absorption that occurs in postmenopausal women. In a previous study, estrogen treatment did not result in an increased intestinal calcium absorption using strontium as a marker. A possible explanation could be that the calcium/strontium load given to the women was too high ( approximately 600 mg Ca), which might result in an insensitive test with respect to the possible stimulation of active strontium transport by estrogen. Therefore, the purpose of this study was to reinvestigate the effect of estrogen on active intestinal strontium absorption using a load of 2.5 mmol of strontium only.


METHODS
the effect of estrogen on intestinal strontium absorption was measured in eight normal postmenopausal women. The study included two baseline strontium absorption tests, which were performed with an interval of 10 days for calculating the within subject variation (SER). Thereafter the effect of 2 months of estrogen treatment on intestinal strontium absorption was assessed. Fractional absorption (FC(240)) and the area under the concentration time curve (AUC) 4 h after an oral strontium load of 2.5 mmol were calculated.


RESULTS
the within subject SER of FC(240) and AUC(0-240) were 2.3+/-0.76 and 1.2+/-0.41, respectively. FC(240) and AUC(0-240) of strontium were unchanged after treatment with estrogen.


CONCLUSIONS
in normal postmenopausal women, we did not find a modulating effect of short-term treatment with a (supra) physiological dose of estrogen on intestinal calcium absorption as measured by the strontium absorption test.
Dijkgraaf-ten Bolscher
M
M
Department of Endocrinology, University Hospital Vrije Universiteit, Room Br 232, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Neele
S J
SJ
Barto
R
R
van der Vijgh
W J
WJ
Netelenbos
J C
JC
D019540:Area Under Curve; D002118:Calcium / Q000097:blood / Q000493:pharmacokinetics*; D004100:Dihydroxycholecalciferols / Q000097:blood; D004958:Estradiol / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects* / Q000502:physiology; D008875:Middle Aged; D010024:Osteoporosis / Q000628:therapy; D017698:Postmenopause / Q000187:drug effects* / Q000378:metabolism; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013324:Strontium / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors
D004100:Dihydroxycholecalciferols; D004966:Estrogens, Conjugated (USP); D004958:Estradiol; D002118:Calcium; D013324:Strontium